A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
- DOI
- 10.1136/jitc-2020-000642
- Published
- 2020-07
- Container
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2020-000642,
title = {A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone},
author = {Julie N Graff and Tomasz M Beer and Joshi J Alumkal and Rachel E Slottke and William L Redmond and George V Thomas and Reid F Thompson and Mary A Wood and Yoshinobu Koguchi and Yiyi Chen and Emile Latour and Raymond C Bergan and Charles G Drake and Amy E Moran},
year = {2020},
journal = {Journal for ImmunoTherapy of Cancer},
doi = {10.1136/jitc-2020-000642},
url = {https://doi.org/10.1136/jitc-2020-000642}
}RIS
TY - JOUR TI - A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone AU - Julie N Graff AU - Tomasz M Beer AU - Joshi J Alumkal AU - Rachel E Slottke AU - William L Redmond AU - George V Thomas AU - Reid F Thompson AU - Mary A Wood AU - Yoshinobu Koguchi AU - Yiyi Chen AU - Emile Latour AU - Raymond C Bergan AU - Charles G Drake AU - Amy E Moran PY - 2020 JO - Journal for ImmunoTherapy of Cancer DO - 10.1136/jitc-2020-000642 UR - https://doi.org/10.1136/jitc-2020-000642 ER -
APA
Graff, J. N., Beer, T. M., Alumkal, J. J., Slottke, R. E., Redmond, W. L., Thomas, G. V., Thompson, R. F., Wood, M. A., Koguchi, Y., Chen, Y., Latour, E., Bergan, R. C., Drake, C. G., & Moran, A. E. (2020). A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-000642
Source records
- crossref · retrieved 2026-09-26T05:23:37.178Z